Analysed PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) News Sources
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
08-04-2026
yahoo.com
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
12-11-2025
yahoo.com
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
06-11-2025
yahoo.com
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
03-11-2025
yahoo.com
Psyence Biomedical Ltd. (PBM) Achieves Breakthrough in High-Purity Ibogaine Production
02-09-2025
yahoo.com
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
28-08-2025
yahoo.com
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
31-07-2025
yahoo.com
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
25-06-2025
yahoo.com
What is the current price of PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ)?
The current price of PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) is $0.0181.
PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) absolute price change since previous trading day?
The absolute price change of PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) since the previous trading day is $0.
PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) percentage price change since previous trading day?
The percentage price change of PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ)?
The most recent average sentiment score for PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ)?
The most recent sentiment for PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ) is .
SEC-8K** Filing Available For PSYENCE BIOMEDICAL LTD (PBMWW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.